- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
RAS Pathway Alterations in Pediatric AML Patients (ENMCC - Hall D) - Nov 4, 2022 - Abstract #ASH2022ASH_4150; Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients...Patients With Acute Myeloid Leukemia and RAS Mutations Benefit Most From Postremission High-Dose Cytarabine: A Cancer and Leukemia Group B Study...Clinical significance of RAS pathway alterations in pediatric acute myeloid leukemia. Haematologica 107, 583–592 (2022).
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, FT596 / Fate Therap
High-Density Cryopreservation of Off-the-Shelf CAR-NK Cells Facilitates On-demand Treatment Access (ENMCC - Hall D) - Nov 4, 2022 - Abstract #ASH2022ASH_2916; HD-Fill of FT596 also showed similar cytolytic potency against Nalm6 leukemia cells compared to the standard dose...In summary, we demonstrate the successful generation of HD-fill CAR-iNK cells without interfering with drug product integrity, identity, and function. HD-fill for off-the-shelf immunotherapies will enable flexibility to clinicians and patients in the out-patient setting for the treatment of hematologic and solid tumors.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Antibody Delivery into the Brain by Radiosensitizer Nanoparticles for Targeted Glioblastoma Therapy. (Pubmed Central) - Nov 4, 2022 Standard of care treatment, consisting of temozolomide (TMZ) and adjuvant radiotherapy (RT), mostly does not prevent local recurrence...Here, we developed a combined strategy using radiosensitizer gold nanoparticles coated with insulin to cross the blood-brain barrier and shuttle tumor-targeting antibodies (cetuximab) into the brain...Histological analysis of tumors showed that the combined treatment eradicated tumor cells, and decreased tumor vascularization, proliferation, and repair. Our findings demonstrate radiosensitizer nanoparticles that effectively deliver antibodies into the brain, target the tumor, and effectively improve standard of care treatment outcome in glioblastoma.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Review, Journal, IO biomarker: EGFR pathway targeting drugs in head and neck cancer in the era of immunotherapy. (Pubmed Central) - Oct 30, 2022 Currently, the EGFR monoclonal antibody (mAb) cetuximab is the only FDA approved RTK-targeting drug for the treatment of HNCs...Additionally, Immunotherapy has been found to be effective in 15 to 20% of patients with recurrent or metastatic HNC as a monotherapy. Thus, attempts are underway for the combinatorial treatment of immunotherapy and EGFR mAbs to determine if the recruitment of immune cells in the tumor microenvironment can overcome EGFR resistance.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Toward Optimized Zr-Immuno-PET: Side-by-Side Comparison of [Zr]Zr-DFO-, [Zr]Zr-3,4,3-(LI-1,2-HOPO)- and [Zr]Zr-DFO*-Cetuximab for Tumor Imaging: Which Chelator Is the Most Suitable? (Pubmed Central) - Oct 28, 2022 Of these, [Zr]Zr-DFO*-cetuximab showed a considerably more favorable pharmacokinetic profile with significantly lower liver and spleen retention than [Zr]Zr-3,4,3-(LI-1,2-HOPO)-cetuximab. Since [Zr]Zr-DFO* demonstrates a very high kinetic inertness, paired with a highly favorable pharmacokinetic profile of the resulting antibody conjugate, DFO* currently represents the most suitable chelator candidate for stable Zr-radiolabeling of antibodies and clinical translation.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Identification of immune-related mechanisms of cetuximab induced skin toxicity in colorectal cancer patients. (Pubmed Central) - Oct 28, 2022 Between 2014 and 2017, we prospectively enrolled 38 mCRC patients who underwent chemotherapy with either Cmab or bevacizumab (Bmab) at two hospitals...Skin rash developed in 23 (76.6%) of the 30 patients treated with Cmab plus FOLFIRI, after cycle 1...This study suggests that the inflammatory cytokine levels might be affected by Cmab exposure and are associated with the development of skin rash in mCRC patients. Further studies are warranted to evaluate this interaction in Cmab treated patients.
- |||||||||| Journal: Opposing Effects of EGF Receptor Signaling on Proliferation and Differentiation Initiated by EGF or TSH/EGF Receptor Transactivation. (Pubmed Central) - Oct 26, 2022
We show that TSH/TSHR transactivates EGFR and characterize it as follows: (1) TSH-induced upregulation of thyroid-specific genes is inhibited by 2 inhibitors of EGFR kinase activity, AG1478 and erlotinib; (2) the mechanism of transactivation is independent of an extracellular EGFR ligand by showing that 2 antibodies, cetuximab and panitumumab, that completely inhibited binding of EGFR ligands to EGFR had no effect on transactivation, and by demonstrating that no EGF was detected in media conditioned by thyrocytes incubated with TSH; (3) TSH/TSHR transactivation of EGFR is different than EGFR activation by EGF by showing that EGF led to rapid phosphorylation of EGFR whereas transactivation occurred in the absence of receptor phosphorylation; (4) EGF caused downregulation of EGFR whereas transactivation had no effect on EGFR level; (5) EGF and TSH stimulation converged on the protein kinase B (AKT) pathway, because TSH, like EGF, stimulated phosphorylation of AKT that was inhibited by EGFR inhibitors; and (6) TSH-induced upregulation of thyroid genes was inhibited by the AKT inhibitor MK2206. Thus, TSH/TSHR causes EGFR transactivation that is independent of extracellular EGFR ligand and in part mediates TSH regulation of thyroid hormone biosynthetic genes.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Erasing Giant Folds: Ménétrier's Disease Treated with Cetuximab. (Pubmed Central) - Oct 26, 2022 Thus, TSH/TSHR causes EGFR transactivation that is independent of extracellular EGFR ligand and in part mediates TSH regulation of thyroid hormone biosynthetic genes. No abstract available
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer, Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Journal: A Case of BRAF V600E-Mutant Colorectal Cancer Treated Effectively by Encorafenib, Binimetinib, and Cetuximab Triple Therapy (Pubmed Central) - Oct 26, 2022 Transverse colostomy was performed, and FOLFOXIRI plus bevacizumab(BEV)was administered...After improvement of dermatitis, the patient resumed encorafenib plus binimetinib, improving liver metastases. Eight months after the start of the second- line, the patient has been administered with triple therapy and had stable disease status.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer, Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Journal: A Case of Serous Retinal Detachment after Encorafenib, Binimetinib, and Cetuximab Treatment for BRAF V600E Mutant Colorectal Cancer (Pubmed Central) - Oct 26, 2022 Genetic testing was positive for BRAF V600E mutation, and the patient received 8 mFOLFOXIRI plus bevacizumab therapy courses...On day 4 of re-treatment, the symptoms improved, another dose reduction was performed, and treatment was resumed. Since subjective MEK inhibitor-induced ocular symptoms are often minor, conducting an interview and early ophthalmologic diagnosis is recommended.
- |||||||||| Ibrance (palbociclib) / Pfizer, Bavencio (avelumab) / EMD Serono, Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono
P1 data, Journal: A phase I study of avelumab, palbociclib, and cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma. (Pubmed Central) - Oct 25, 2022 P1 There were, however, no significant differences between each group for OS. The combination of avelumab, cetuximab, and palbociclib was well tolerated and supports further evaluation in patients with R/M HNSCC.
- |||||||||| monalizumab (IPH2201) / AstraZeneca, Innate
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Checkpoint inhibition, IO biomarker, Metastases: INTERLINK-1: Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer (clinicaltrials.gov) - Oct 24, 2022 P3, N=369, Active, not recruiting, Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=624 --> 369 | Trial completion date: Mar 2024 --> Jul 2023 | Trial primary completion date: Mar 2024 --> Jul 2023
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Preclinical, Journal, PD(L)-1 Biomarker, IO biomarker: Platelets upregulate tumor programmed death-ligand 1 in an epidermal growth factor receptor-dependent manner in vitro. (Pubmed Central) - Oct 22, 2022 Both an EGF neutralizing antibody and the drug, Cetuximab (EGF-receptor neutralizing antibody) inhibited platelet-induced increases in tumor cell PD-L1, suggesting that platelets induce tumor cell PD-L1 in an EGFR-dependent manner. Our data reveal a novel mechanism for platelets in tumor immune escape and warrant further investigation to determine if targeting platelets improves ICI therapeutic responses.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Direct CD32 T-cell cytotoxicity: implications for breast cancer prognosis and treatment. (Pubmed Central) - Oct 22, 2022 Sensitive BC cell conjugation with CD32-CR T cells induced CD32 polarization and down-regulation, CD107a release, mutual elimination, and proinflammatory cytokine production unaffected by human IgGs but enhanced by cetuximab...ICAM1 was a major regulator of CD32-CR T cell-mediated cytotoxicity. CD32-CR T cells may help identify cell surface CD32 ligand(s) and novel prognostically relevant transcriptomic signatures and develop innovative BC treatments.
|